Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation, in patients with stable coronary artery disease. A 6 to 12-month randomised double blind parallel groups multicentre study

Trial Profile

Safety of oral chronic administration of ivabradine modified release formulation compared to ivabradine immediate release formulation, in patients with stable coronary artery disease. A 6 to 12-month randomised double blind parallel groups multicentre study

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Coronary artery disease
  • Focus Adverse reactions; Registrational
  • Sponsors IRIS
  • Most Recent Events

    • 22 Jun 2013 Planned number of patients changed from 700 to 850 as reported by European Clinical Trials Database.
    • 23 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top